Dervisoglou Athanasios, Tsiodras Sotirios, Kanellakopoulou Kyriaki, Pinis Stamatios, Galanakis Nearchos, Pierakakis Stephanos, Giannakakis Panagiotis, Liveranou Stavroula, Ntasiou Panagiota, Karampali Efstathia, Iordanou Christos, Giamarellou Helen
Second Department of Surgery, Agios Panteleimon State General Hospital, 79-81 Mpotasi Street, 18537 Piraeus, Greece.
Arch Surg. 2006 Dec;141(12):1162-7. doi: 10.1001/archsurg.141.12.1162.
Cephalosporins are widely used and considered to be effective as prophylaxis in biliary surgery. Nevertheless, they lack activity against enterococci. We conducted a study to compare the efficacy of ampicillin-sulbactam vs cefuroxime in preventing surgical site infections following elective cholecystectomy.
A prospective randomized controlled trial.
A major tertiary care hospital.
Four hundred eighteen randomized patients (of 549 total), who from July 2002 to August 2004 underwent elective open or laparoscopic cholecystectomy with prospective assessment for development of surgical site infections for 1 month postoperatively.
A single intravenous dose of 1.5 g of cefuroxime (group A, n = 207) or 3 g of ampicillin-sulbactam (group B, n = 211) was administered during induction of anesthesia. Bile and gallbladder mucosal cultures were taken intraoperatively from all patients.
Number of postoperative surgical site infections.
A postoperative surgical site infection was noted in 19 (4.5%) of 418 patients, 18 from group A and 1 from group B (P<.001). In the group that received cefuroxime, 15 (83.3%) of 18 surgical site infections were due to Enterococcus species. Intraoperative bactibilia as well as intraoperative gallbladder rupture were associated with surgical site infections (P<.001).
A single dose of ampicillin-sulbactam favored better compared with cefuroxime for prevention of postoperative surgical site infections due to Enterococcus species after elective cholecystectomy. Ampicillin-sulbactam may be a better agent for antimicrobial prophylaxis in high-risk patients undergoing elective cholecystectomy, especially in a setting where the incidence of enterococcal infections is higher.
头孢菌素被广泛使用,并且被认为在胆道手术中作为预防性用药是有效的。然而,它们对肠球菌缺乏活性。我们进行了一项研究,以比较氨苄西林-舒巴坦与头孢呋辛在择期胆囊切除术后预防手术部位感染的疗效。
一项前瞻性随机对照试验。
一家大型三级护理医院。
418名随机分组的患者(总共549名),他们在2002年7月至2004年8月期间接受了择期开放性或腹腔镜胆囊切除术,并对术后1个月手术部位感染的发生情况进行前瞻性评估。
在麻醉诱导期间,静脉注射单剂量1.5g头孢呋辛(A组,n = 207)或3g氨苄西林-舒巴坦(B组,n = 211)。术中从所有患者采集胆汁和胆囊黏膜培养物。
术后手术部位感染的数量。
418名患者中有19名(4.5%)发生了术后手术部位感染,A组18名,B组1名(P<0.001)。在接受头孢呋辛的组中,18例手术部位感染中有15例(83.3%)是由肠球菌引起的。术中胆汁菌血症以及术中胆囊破裂与手术部位感染相关(P<0.001)。
与头孢呋辛相比,单剂量氨苄西林-舒巴坦在预防择期胆囊切除术后由肠球菌引起的手术部位感染方面效果更好。对于接受择期胆囊切除术的高危患者,尤其是在肠球菌感染发生率较高的情况下,氨苄西林-舒巴坦可能是一种更好的抗菌预防药物。